Literature DB >> 25559600

Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.

Timothy M Rawson1, Nataliya Brima, Fahad Almajid, Anton L Pozniak, Azara Janmohamed, Sundhiya Mandalia, Sheena Basnayake, Lusha Kellgren, Andrew J Copas, Robert F Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25559600     DOI： 10.1097/QAI.0000000000000515

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  2 in total

1.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?

Authors:  Giuseppe Losurdo; Andrea Iannone; Floriana Giorgio; Mariabeatrice Principi; Alfredo Di Leo; Enzo Ierardi
Journal:  United European Gastroenterol J       Date:  2015-12-15       Impact factor: 4.623

2.  Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.

Authors:  Yanink Caro-Vega; Anna Schultze; Anne Marie W Efsen; Frank A Post; Alexander Panteleev; Aliaksandr Skrahin; Jose M Miro; Enrico Girardi; Daria N Podlekareva; Jens D Lundgren; Juan Sierra-Madero; Javier Toibaro; Jaime Andrade-Villanueva; Simona Tetradov; Jan Fehr; Joan Caylà; Marcelo H Losso; Robert F Miller; Amanda Mocroft; Ole Kirk; Brenda Crabtree-Ramírez
Journal:  BMC Infect Dis       Date:  2018-04-23       Impact factor: 3.090
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.